

Annual General Meeting Statement

Rehovot, Israel, 1 August 2005 – XTL Biopharmaceuticals Ltd. (“XTLbio”) announced that at its Annual General Meeting held earlier today at XTLbio’s offices, all the resolutions proposed to the shareholders were approved. As planned, later today the Company will hold an Extraordinary General Meeting (EGM). We will notify the shareholders of the results of the EGM after the meeting.

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer

Tel: +972 8 930 4440

Notes to Editors

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing drugs against hepatitis. Established in 1993, XTLbio became a public company in 2000 and its ordinary shares are listed on the Official List of the UK Listing Authority and are traded on the London Stock Exchange under the symbol XTL and in the Tel Aviv Stock Exchange, Israel.